ArticleSN comprehensive clinical medicine2021
Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity.
Article in SN comprehensive clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Oral Manifestations of COVID-19 in Hospitalized Patients: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Article
- Article
- Evaluation of link between COVID-19 adjacent spike in hydroxychloroquine use and increased reports of pemphigus: a disproportionality analysis of the FDA Adverse Event Reporting System.Frontiers in immunology · 2024Observational
- [Reactivation of an ocular mucous membrane pemphigoid due to zoster ophthalmicus and COVID-19].Die Ophthalmologie · 2024Article
- New-onset of pemphigus following COVID-19 infection: A case report.SAGE open medical case reports · 2024Article
- A Rare Case of COVID-19-Induced Acute Exacerbation of Oral Dermatitis Herpetiformis in a Geriatric Patient.International medical case reports journal · 2023Article
- The Oral Lesion in the COVID-19 Patient: Is It True Oral Manifestation or Not?Infection and drug resistance · 2023Review
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- Pemphigus vulgaris after COVID-19 infection and vaccination.Journal of the American Academy of Dermatology · 2022Article
- Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination.Biomedicines · 2022Review
- New-onset pemphigus foliaceus following SARS-CoV-2 infection and unmasking multiple sclerosis: A case report.Clinical case reports · 2022Article
- Pemphigus foliaceous after mRNA COVID-19 vaccineEuropean journal of dermatology : EJD · 2022Article
- New onset of pemphigus foliaceus following BNT162b2 vaccine.Dermatologic therapy · 2022Article
- The multifactorial complexities of autoimmune development in Pemphigus vulgaris: Critical evaluation of the role of environmental and lifestyle "exposome" factors.Frontiers in immunology · 2022Review
- Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician.Clinical, cosmetic and investigational dermatology · 2022Review
- Diagnosis and Treatment Challenges of an Atypical Case of Pemphigus vulgaris During the COVID-19 Pandemic.Cureus · 2022Article
- Coexistence of Pemphigus Vulgaris and Lichen Planus following COVID-19 Vaccination.Case reports in dermatological medicine · 2022Article
- COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus.Dermatologic therapy · 2022Review
- Case Report: Infantile Bullous Pemphigoid: Triggering by COVID-19 Is Speculative.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullae autoimmune diseases can be induced by environmental factors in a genetically susceptible individual, and viruses may be important triggers for this process. Coronavirus disease 2019 (COVID-19) is a multisystemic disease known for developing many types of skin lesions. However, little is known about post-COVID-19 manifestations. A previous healthy male patient, 43 years old, with resistant mediastinal Hodgkin's lymphoma stage II diagnosed in 2019, without treatment at the moment, developed monomorphic flaccid bullae on the trunk 40 days after testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although he had risk factors for IgA and paraneoplastic pemphigus, there were no elements for these diseases. The investigation confirmed a pemphigus vulgaris (PV). PV had a good response to treatment with prednisolone 1 mg/kg per day, and methotrexate 15 mg subcutaneously was added per week. The patient was discharged with oral methotrexate and prednisolone at the same dose. Prednisolone was decreased by 20 mg per day during the follow-up. Viruses such as herpesvirus, cytomegalovirus, and varicela zoster can act as triggers for PV. This process is not immediate after the infection because it depends on the change in antibodies initially produced against the virus that start to identify antigens present in the skin's anchoring structures. SARS-CoV-2 can induce autoimmunity, as seen in Guillán-Barré syndrome and in Kawasaki disease. It is a highly immunogenic virus that is the perfect agent for triggering PV. This case can be considered a cutaneous autoimmune post-COVID-19 manifestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.